News
Cantor Fitzgerald kicked off coverage of Merck with a neutral rating and a price target of $85, triggering a chorus of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback